Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT02318693 für Typ-2-Diabetes mellitus ist abgeschlossen. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355) Phase 4 53 Kurzzeitig
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT02318693 untersuchte Behandlung im Zusammenhang mit Typ-2-Diabetes mellitus. Diese interventionsstudie der Phase 4 hat den Status abgeschlossen. Die Studie begann am 4. Februar 2015 mit 53 Teilnehmern. Sie wurde durchgeführt von Merck und am 15. Dezember 2015 abgeschlossen. Die Daten von ClinicalTrials.gov wurden zuletzt am 21. August 2018 aktualisiert.
Kurzbeschreibung
This is a study of the efficacy of sitagliptin and glibenclamide in a short-term treatment on the glucose variability using continuous glucose monitoring (CGM) in Japanese participants with type 2 diabetes mellitus (T2DM). The primary hypothesis is that treatment with sitagliptin will be superior to treatment with glibenclamide in the change from baseline in mean amplitude of glycemic excursions (MAGE) through contin...Mehr anzeigen
Offizieller Titel
A Randomized, Open-label, Comparative Clinical Trial to Study the Efficacy of Sitagliptin and Glibenclamide in a Short Term Treatment on the Daily Glucose Variability Using Continuous Glucose Monitoring (CGM) in Japanese Patients With Type 2 Diabetes Mellitus
Erkrankungen
Typ-2-Diabetes mellitusPublikationen
Wissenschaftliche Artikel und Forschungspapiere zu dieser klinischen Studie:Weitere Studien-IDs
- 0431-355
- 152867 (Registerkennung) (JAPIC-CTI)
NCT-Nummer
Studienbeginn (tatsächlich)
2015-02-04
Zuletzt aktualisiert
2018-08-21
Studienende (vorauss.)
2015-12-15
Geplante Rekrutierung
53
Studientyp
Interventionsstudie
PHASE
Phase 4
Status
Abgeschlossen
Primäres Ziel
Behandlung
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
ExperimentellSitagliptin 50 mg Sitagliptin 50 mg administered orally once daily before breakfast for 14 days. | Sitagliptin Sitagliptin 50 mg orally once a day before breakfast for 14 days |
Aktives VergleichspräparatGlibenclamide 2.50 mg TDD Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose. | Glibenclamide Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13 | MAGE is a popular metric for assessment of major (e.g., postprandial) glucose swings. MAGE is calculated as the average of differences between consecutive glucose peaks and nadirs greater than 1 standard deviation (SD) of 24-hour mean glucose. In this assessment, glucose levels were determined using continuous glucose monitoring (CGM) over 24 hours at Baseline and Day 13; CGM values were further corrected for blood glucose values obtained via participant-administered finger-stick. Least squares (LS) means values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome. | Baseline (Day -2) and Day 13 |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Change From Baseline in the Standard Deviation of Blood Glucose Levels | SD is a popular metric for assessment of postprandial glucose swings. The SD of all glycemic excursions over 24 hours (i.e., total of 288 glucose values over 24 hours) was determined for Baseline and Day 13. Original values were obtained using CGM and corrected for blood glucose values obtained via participant-administered finger-stick. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome. | Baseline (Day -2) and Day 13 |
Change From Baseline in Maximum Incremental Postprandial Glucose Levels in Each Meal | The peak postprandial glucose level during the 3 hours post meal minus the preprandial glucose level 1 hour before meal was determined for corrected CGM values at Baseline and Day 13 for breakfast, lunch, and dinner. Meals were standardized with respect to total calories, and protein, fat, and carbohydrate composition as well as timing of administration. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates better control of postprandial glucose. | Baseline (Day -2) and Day 13 |
Change From Baseline in 24-hour Mean Glucose Level | The mean glucose level over 24-hours at Baseline and Day 13 was determined using CGM values corrected for participant-administered finger-stick values. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome. | Baseline (Day -2) and Day 13 |
Change From Baseline in Percentage of Hypoglycemic Values (Glucose Sensor Readings: < 70, <60, <50 mg/dL) | Hypoglycemia, defined as low blood glucose, is a common side effect of medications used to treat diabetes mellitus type 2. The percentage of hypoglycemic corrected CGM readings (sensor glucose \<70, \<60, \<50 mg/dL) over a 24-hour period were determined at baseline and Day 13. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates improvement in occurrence of hypoglycemia. | Baseline (Day -2) and Day 13 |
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
20 Years
Zugelassene Geschlechter
Alle
- Japanese participants with a diagnosis of Type 2 diabetes mellitus
- History of Type 1 diabetes mellitus or ketoacidosis
- History of insulin or thiazolidinedione (including fixed-dose drug combinations containing one of these drugs) in the 12 weeks before study participation
Keine Kontaktdaten vorhanden
Keine Standortdaten vorhanden